Objective -To determine the levels of various biochemical forms of the placental protein, inhibin (total inhibin, inhibin A, and a inhibin precursor) and activin in maternal serum samples from fetal Down's syndrome, and to determine which of these analytes most effectively identifies samples from affected pregnancies. Methods -Maternal serum samples were collected from 100 unaffected pregnancies and 20 cases of fetal Down's syndrome during gestational weeks 15-20 for routine triple marker screening, and were stored frozen after clinical assay. Levels of inhibin A, total inhibin, a inhibin precursor (pro-aC), and activin were compared retrospectively in the Down's syndrome cases and control samples.
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Results -There was no association of the inhibin or activin levels with gestational age or length of freezer storage, and therefore single median values were determined for the unaffected pregnancies for each analyte. Multiples of the unaffected median (MoM) values were calculated for all cases, showing that inhibin A (1.95 MoM) provided the best discrimination between cases and controls, followed by total inhibin (1.37 MoM). Mann-Whitney U analysis showed significant group differences in inhibin A (P =0.0001) and total inhibin (P = 0.0005). In contrast, a inhibin precursor (0.81 MoM) and activin (1.16 MoM) levels in Down's syndrome cases were not significantly different from those in unaffected patients. Conclusions -Levels ofinhibin A and total inhibin, but not a inhibin precursor or activin, are significantly raised in maternal serum from cases of fetal Down's syndrome. These data, taken together, indicate that inhibin A levels are specifically raised in Down's syndrome pregnancy. 45% of the inhibin A levels in the Down's syndrome samples were above the 90th centile of unaffected levels, indicating that inhibin A may be as good a marker as human chorionic gonadotrophin, the most informative serum marker currently in use.
Prenatal serum screening for fetal Down's syndrome in the second trimester using combinations of a fetoprotein (AFP), human chorionic gonadotrophin (bCG), and unconjugated oestriol (uE 3 ) , has become common practice in recent years. 1 2 The most informative of the serum markers is the placental product, hCG, and its free~subunit.' In fact, almost every product of the placenta that has been measured in maternal serum during the second trimester, including the free a subunit of hCG, human placental lactogen, Schwangershaft protein, and progesterone, has been shown to be raised in fetal Down's syndrome."
Despite the success of the triple marker approach (about 65% detection rate at a false positive rate of 5%),5 there is room for improvement in detection of fetal Down's syndrome. Previous data have indicated that another placental protein, inhibin, is also raised in maternal serum from second trimester Down's syndrome pregnancy.t" However, inhibin is secreted in multiple biochemical forms, including a inhibin subunits and a./~A (inhibin A) and a./~B (inhibin B) heterodimers. All these forms (total inhibin) are measured simultaneously in radioimmunoassays that use a subunit directed antisera. 9 -11 Two site immuno metric assays specific for different biochemical forms of inhibin have been developed recently, including those for inhibin N 2 13 and a inhibin subunit precursor (pro-aC) proreins." New data show that, in addition to the previously observed rise in total inhibin, levels of inhibin A are also increased in maternal serum of Down's syndrome pregnancies.":" Serum levels of pro-aC have not yet been studied in Down's syndrome pregnancy.
Two~subunits of inhibin can form dimers, called activins, whose actions oppose those of inhibin." Beta subunit mRNA 2°-22 and protein" have been localised to the placenta, and activin has been shown to stimulate placental hCG synthesis in vitro." Therefore, maternal serum levels of activin also may be raised in Down's syndrome pregnancy.
The objective of this study was to compare the levels of various forms of inhibin (total inhibin, inhibin A, and a subunit precursor) and of activin in second trimester maternal serum samples from Down's syndrome and unaffected pregnancies, and to determine which of these forms most effectively identifies the affected pregnancies.
INHIBIN A ASSAY
Samples were measured in triplicate with a two site enzyme linked immunosorbent assay (ELISA) specific for inhibin A (Harlan Bioproducts, Indianapolis, IN). Methods were as described previously," The assay standard was the same human recombinant 32 kD inhibin A used in the total inhibin radioimmunoassay.
ACTIVIN ASSAY
Activin was measured by a competitive binding assay using follistatin as a capture molecule, as previously described." This assay does not measure activin bound to endogenous follistatin, and is therefore referred to as a "free" activin assay. FoIlistatin was provided by the NIDDK National Hormone and Pituitary Reagents Program, Bethesda, MD, and human recombinant activin A used for standard and radiolabel was provided by Genentech Research Reagents Program. A mid-gestation pregnancy serum pool was used to verify parallelism and recovery of activin in this assay (data not shown).
In all assays each case-control set of six samples was tested together and without knowledge by the operator of which sample was the Down's syndrome case. Intra-assay coefficients of variation were less than 10% for all assays. For each analyte, mass units were converted to multiples of the unaffected median (MoM), and were log transformed before statistical analyses.
INHffilN a PRECURSOR (mo-ue) ASSAY Samples were measured in duplicate after appropriate dilution using an ELISA kit (Serotee Ltd, Oxford, UK) as previously described. ,. This assay specifically measures proteins that contain the pro region of the a inhibin subunit, in either free a monomer or aJ~dimer forms.
TOTAL INHffilN ASSAY Samples were tested in duplicate by radioimmunoassay using the Monash 1989 antiserum" as previously described." Human recombinant 32 kD inhibin A (Genentech Research Reagents Program, South San Francisco, CA) was used as assay standard and as radiolabel after iodination with chloramine T. The Monash antiserum measures free a subunits, as well as inhibin A 9 10 and inhibin B.II
Twenty cases of fetal Down's syndrome, which had sufficient serum in freezer storage, were identified in women having triple marker screening between 15 and 20 completed gestational weeks at Women and Infants Hospital from April 1992 to January 1994. Fifteen of the cases were identified as screen positive for increased risk of Down's syndrome, and five were screen negative. Each case was matched to five samples from unaffected singleton pregnancies for length of freezer storage (± one week), and were collected during weeks 15-19 of gestation. All samples in the study had been assayed upon receipt for AFP, uE 3 , and hCG before freezing at -20°C.
* Denotes a statistically significant correlation between analyte values.
All data were log transformed for analyses.
All data were log transformed for analyses. 
Results
The levels of total inhibin, inhibin A, a inhibin precursor, and activin were compared in 100 unaffected pregnancies and 20 Down's syn-drome pregnancies. Because there was little or no association of the levels of any of the four analytes with gestational age in the time period studied or with length of freezer storage, single median values for the unaffected pregnancies were determined. The median MoM values in Down's syndrome cases were 1.95, 1.37, 0.81, and 1. 16 MoM for inhibin A, total inhibin, pro-aC, and activin, respectively. Levels of maternal serum inhibin A and total inhibin were significantly higher in Down's syndrome than in unaffected pregnancies, while levels of pro-aC and activin were not different between groups (table 1) . Inhibin A levels showed the greatest difference between cases and controls, with 45% (9/20) of the cases observed above the 90th centile of unaffected and 30% above the 95th centile. For total inhibin, 25% of the cases observed were above the 90th and 95th centiles (fig 1) . To assess the extent to which the four analytes may share common forms or patterns of secretion, the correlation between pairs of these analytes was examined in both cases and controls (table 2) . Correlation between analyres was not significant except for inhibin A and total inhibin in both cases (R = 0.51, P = 0.02) and controls (R =0.27, P =0.01).
Because inhibin A appears to be the most effective of the analytes studied, we examined more closely the distribution of its values in the cases and controls. Inhibin A MoM values for cases and controls fit a log Gaussian distribution reasonably well between at least the 10th and 90th centiles (fig 2) . Figure 3 shows the modelled distribution curves for cases and controls. Table 3 shows the correlation of inhibin A levels with the levels of the currently used triple markers in the same samples. Levels of inhibin A in maternal serum were significantly correlated with hCG levels for both cases (R = 0.67, P =0.001) and controls (R =0.33, P =0.001), but were not correlated with levels of AFP or uE in either cases or controls.
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Discussion
The results of this study confirm and expand on previous reports1 5 17 showing that maternal serum levels of inhibin A and total inhibin in the second trimester are raised in cases of Down's syndrome .·0 . 0·2 0·3 0·5 0·7 1 2 3 5 7 10 20
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A levels for both cases (r = 0.3Q-{).42) and controls (r = 0.24-0.42).17 18 In the present study the hCG and inhibin A correlation was similarly low for controls, but was considerably higher for cases. Our finding of a high correlation in Down's syndrome samples may be due to the relatively small number of cases studied. The reason that levels of inhibin A in Down's syndrome cases are raised more than those of total inhibin is probably related to the specific forms of inhibin secreted into the maternal circulation in such cases. Total inhibin is defined as those inhibin forms that are recognised by a directed antisera, and can include inhibin A, inhibin B, and various a subunits. Therefore, because inhibin A levels are raised more than total inhibin, it follows that inhibin B and/or a inhibin subunit levels should be relatively unchanged or lower in cases of Down's syndrome. Our data using a pro-aC inhibin assay showed that precursor forms of the a inhibin subunit were slightly lower in cases than in controls, thus providing evidence that inhibin A levels are specifically raised in Down's syndrome pregnancy. Maternal serum levels of inhibin B in Down's syndrome pregnancy have not yet been studied. This is the first report of maternal serum levels of activin in Down's syndrome pregnancies and shows that such levels are the same in cases and controls. However, the methodology used takes advantage of the high affinity interaction of activin and its binding protein, follistatin, and thus preferentially measures serum "free" activin. In a third trimester pregnancy serum sample, follistatin immunoreactivity was detected predominantly at molecular weight sizes greater than that of free follistatin; an observation consistent with the presence of follistatin-activin complexes:" Activin bound by follistatin was not measured in the assay used in this study and must be examined before we can draw conclusions about the secretion of activin in Down's syndrome pregnancy.
The lack of correlation between pro-aC and total inhibin assay values was unexpected. In our study it seems that second trimester levels of pro-aC in maternal serum were lower than levels reported for the first trimester of pregnancy," a panern similar to that for total inhibin." In addition, in one patient studied," pro-aC and total inhibin levels in serum samples from the normal menstrual cycle were significantly correlated. However, although both assays measure a inhibin subunits, different epitopes are targeted. In the total inhibin radioimmunoassay, a single C terminal directed" polyclonal antiserum is used to measure all inhibin forms that contain the mature a inhibin subunit; this includes pro-aC, which exhibits 288% cross reactivity." In contrast, the pro-aC assay measures a inhibin precursor proteins only by using a capture antibody directed to the pro region of the precursor. The lack of correlation supports previous data suggesting that maternal serum contains multiple a inhibin forms," some of which are appar- pregnancy. In both studies the degree of elevation of dimeric inhibin A was more pronounced than that of total inhibin. In the study of Cuckle et af7 the median inhibin A level was 1.59 MoM, somewhat lower than our result of 1.95 MoM. However, the level of total inhibin was similar in both studies (1.31 MoM in Cuckle et atand 1.37 MoM in this study). The use ofinhibin A measurement in Down's syndrome screening is supported by the recent study of Wald et al," who examined 77 cases and 1355 controls and found a median inhibin A level of 1.79 MoM in the cases. They determined that an increase in detection rate of as much as 10% at a fixed 5% false positive rate may be achieved by the addition of inhibin A measurement to triple marker screening.
Univariately, nine of the 20 Down's syndrome cases had inhibin A levels greater than the 90th centile of control values, a detection rate (45%) similar to that obtained with hCG, the most informative of the triple markers. In this study the univariate detection rate using hCG was 40%, consistent with previously published estimates of about 50%.' For purposes of comparison, the univariate detection rates of AFP and uE 3 were 20% and 25%, respectively, in the current study. Previous studies have reported a low correlation of hCG and inhibin ently recognised differently in the two a subunit directed assays. Absolute levels of inhibin A in pregnancy serum may vary widely depending on the assay and calibration standard used. In reports using the same assay, but different calibration standards, the mean second trimester inhibin A levels in unaffected pregnancies ranged from 77 (present study) to 920 pg/ml." However, the ratio of inhibin A levels in Down's syndrome and unaffected pregnancies remains similar (1.59-2.60 MoM) regardless of the calibration standard used. 15 -18 These data reinforce the importance of establishing an international standard for inhibin A that can be used for calibrating assays, with each laboratory generating its own set of medians, and expressing results for prenatal serum screening as MoM values.
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